Abbvie Stock Surges on Patent Extension for Rinvoq as $1.68 Billion Volume Ranks 43rd in Market Activity

, , , ranking 43rd in market activity. The stock’s rally was driven by extended patent protection for its key drug Rinvoq, delaying generic competition until 2037. The settlement with generic manufacturers adds five years of exclusivity beyond prior expectations, reinforcing the drug’s revenue potential. , positioning it as a critical growth driver for AbbVie’s immunology portfolio.

Institutional investors bolstered their stakes in the first quarter, with Ransom Advisory, Goldman Sachs, and Vanguard increasing holdings. , , . Despite insider sales by executives like Azita Saleki-Gerhardt and Nicholas Donoghue, , respectively, .

Analysts revised price targets following the patent extension, . However, , . .

The back-test strategy for a high-liquidity rotation approach requires defining an investable universe, retrieving volume data, and building a daily rebalancing portfolio. Current tools are limited to single-ticker analyses, so the user must clarify whether to narrow the test to a specific index (e.g., S&P 500), a single stock, or propose an alternative methodology for multi-asset testing.